Corrigendum: Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling (Journal of Clinical Investigation (2017) 127:11 (4059-4074) DOI: 10.1172/JCI94585);Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling

Journal of Clinical Investigation

Volumn 127, Issue 11, 2017, Pages 4059-4074

  Softic, Samir ^a,b   Gupta, Manoj K ^c   Wang, Guo Xiao ^a   Fujisaka, Shiho ^a,d   O'Neill, Brian T ^a,e   Rao, Tata Nageswara ^a,f   Willoughby, Jennifer ^g   Harbison, Carole ^g   Fitzgerald, Kevin ^g   Ilkayeva, Olga ^h   Newgard, Christopher B ^h   Cohen, David E ⁱ   Kahn, C Ronald ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d UNIVERSITY OF TOYAMA   (Japan)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

^g ALNYLAM PHARMACEUTICALS   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A; CARBOHYDRATE RESPONSIVE ELEMENT BINDING PROTEIN; FRUCTOSE; GLUCOSE; KETOHEXOKINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FATTY ACID; FRUCTOKINASE; INSULIN; TRANSCRIPTION FACTOR; TRANSCRIPTOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; CELL LYSATE; COMPARATIVE STUDY; CONTROLLED STUDY; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FRUCTOSE METABOLISM; GLUCOSE INTAKE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HEPATOMEGALY; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INSULIN SIGNALING; INSULIN TOLERANCE TEST; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIVER BIOPSY; LIVER METABOLISM; MALE; METABOLOMICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK FACTOR; RNA ANALYSIS; RNA SEQUENCE; SUGAR INTAKE; SUGAR-SWEETENED BEVERAGE; WESTERN BLOTTING; ADOLESCENT; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENETICS; LIVER; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION;

ADOLESCENT; ANIMALS; DIET, HIGH-FAT; ENZYME INDUCTION; FATTY ACIDS; FRUCTOKINASES; FRUCTOSE; GLUCOSE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPOGENESIS; LIVER; MALE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTIONAL ACTIVATION; TRANSCRIPTOME; UP-REGULATION;

EID: 85032896266     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI99009     Document Type: Erratum

References (65)

1. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u. s. Adults. Diabetes Care. 2004;27(10):2444-2449.
2. Gotto AM, et al. The metabolic syndrome: a call to action. Coron Artery Dis. 2006;17(1):77-80.
3. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686-690.
4. Ebbeling CB, et al. A randomized trial of sugar-sweetened beverages and adolescent body weight. N Engl J Med. 2012;367(15):1407-1416.
5. Ma J, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol. 2015;63(2):462-469.
6. de Ruyter JC, Olthof MR, Seidell JC, Katan MB. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med. 2012;367(15):1397-1406.
7. Gaby AR. Adverse effects of dietary fructose. Altern Med Rev. 2005;10(4):294-306.
8. Nakagawa T, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625-F631.
9. Softic S, Cohen DE, Kahn CR. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease. Dig Dis Sci. 2016;61(5):1282-1293.
10. Chong MF, Fielding BA, Frayn KN. Mechanisms for the acute effect of fructose on postprandial lipemia. Am J Clin Nutr. 2007;85(6):1511-1520.
11. Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science. 2008;320(5882):1492-1496.
12. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125-1131.
13. Postic C, Dentin R, Denechaud PD, Girard J. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu Rev Nutr. 2007;27:179-192.
14. Kim MS, et al. ChREBP regulates fructoseinduced glucose production independently of insulin signaling. J Clin Invest. 2016;126(11):4372-4386.
15. An J, et al. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004;10(3):268-274.
16. Newgard CB. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 2012;15(5):606-614.
17. Horton JD, Bashmakov Y, Shimomura I, Shimano H. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA. 1998;95(11):5987-5992.
18. Herman MA, et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature. 2012;484(7394):333-338.
19. Bricambert J, Miranda J, Benhamed F, Girard J, Postic C, Dentin R. Salt-inducible kinase 2 links transcriptional coactivator p300 phosphorylation to the prevention of ChREBP-dependent hepatic steatosis in mice. J Clin Invest. 2010;120(12):4316-4331.
20. Xu X, So JS, Park JG, Lee AH. Transcriptional control of hepatic lipid metabolism by SREBP and ChREBP. Semin Liver Dis. 2013;33(4):301-311.
21. Fisher FM, et al. A critical role for ChREBPmediated FGF21 secretion in hepatic fructose metabolism. Mol Metab. 2017;6(1):14-21.
22. Sae-Lee C, Moolsuwan K, Chan L, Poungvarin N. ChREBP regulates itself and metabolic genes implicated in lipid accumulation in ?-cell line. PLoS ONE. 2016;11(1):e0147411.
23. Barbour LA, et al. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem. 2005;280(45):37489-37494.
24. Hirosumi J, et al. A central role for JNK in obesity and insulin resistance. Nature. 2002;420(6913):333-336.
25. Dominici FP, Hauck S, Argentino DP, Bartke A, Turyn D. Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice. J Endocrinol. 2002;173(1):81-94.
26. Asipu A, Hayward BE, O'Reilly J, Bonthron DT. Properties of normal and mutant recombinant human ketohexokinases and implications for the pathogenesis of essential fructosuria. Diabetes. 2003;52(9):2426-2432.
27. Kleiner DE, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.
28. de Koning L, Malik VS, Kellogg MD, Rimm EB, Willett WC, Hu FB. Sweetened beverage consumption, incident coronary heart disease, and biomarkers of risk in men. Circulation. 2012;125(14):1735-1741.
29. Pettinelli P, Videla LA. Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011;96(5):1424-1430.
30. Benhamed F, et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest. 2012;122(6):2176-2194.
31. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002;277(11):9520-9528.
32. Dentin R, et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice. Diabetes. 2006;55(8):2159-2170.
33. Monetti M, et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 2007;6(1):69-78.
34. Yamaguchi K, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45(6):1366-1374.
35. Puri P, et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007;46(4):1081-1090.
36. Tandra S, et al. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol. 2011;55(3):654-659.
37. Aeberli I, et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care. 2013;36(1):150-156.
38. Ludwig DS, Majzoub JA, Al-Zahrani A, Dallal GE, Blanco I, Roberts SB. High glycemic index foods, overeating, and obesity. Pediatrics. 1999;103(3):E26.
39. Ebbeling CB, Leidig MM, Sinclair KB, Hangen JP, Ludwig DS. A reduced-glycemic load diet in the treatment of adolescent obesity. Arch Pediatr Adolesc Med. 2003;157(8):773-779.
40. Steinert RE, Frey F, Topfer A, Drewe J, Beglinger C. Effects of carbohydrate sugars and artificial sweeteners on appetite and the secretion of gastrointestinal satiety peptides. Br J Nutr. 2011;105(9):1320-1328.
41. Stanhope KL, et al. Consuming fructosesweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119(5):1322-1334.
42. Tappy L, Le KA. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev. 2010;90(1):23-46.
43. White JS. Challenging the fructose hypothesis: new perspectives on fructose consumption and metabolism. Adv Nutr. 2013;4(2):246-256.
44. Rizkalla SW. Health implications of fructose consumption: A review of recent data. Nutr Metab (Lond). 2010;7:82.
45. Shapiro A, Mu W, Roncal C, Cheng KY, Johnson RJ, Scarpace PJ. Fructose-induced leptin resistance exacerbates weight gain in response to subsequent high-fat feeding. Am J Physiol Regul Integr Comp Physiol. 2008;295(5):R1370-R1375.
46. Burmeister MA, Ayala J, Drucker DJ, Ayala JE. Central glucagon-like peptide 1 receptor-induced anorexia requires glucose metabolismmediated suppression of AMPK and is impaired by central fructose. Am J Physiol Endocrinol Metab. 2013;304(7):E677-E685.
47. Zubiria MG, Alzamendi A, Moreno G, Rey MA, Spinedi E, Giovambattista A. Long-Term Fructose Intake Increases Adipogenic Potential: Evidence of Direct Effects of Fructose on Adipocyte Precursor Cells. Nutrients. 2016;8(4):198.
48. Marek G, et al. Adiponectin resistance and proinflammatory changes in the visceral adipose tissue induced by fructose consumption via ketohexokinase-dependent pathway. Diabetes. 2015;64(2):508-518.
49. Kohli R, et al. High-fructose, medium chain trans fat diet induces liver fibrosis and elevates plasma coenzyme Q9 in a novel murine model of obesity and nonalcoholic steatohepatitis. Hepatology. 2010;52(3):934-944.
50. Zelber-Sagi S, et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study. J Hepatol. 2007;47(5):711-717.
51. Thuy S, et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr. 2008;138(8):1452-1455.
52. Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;146(3):726-735.
53. Ouyang X, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol. 2008;48(6):993-999.
54. Papandreou D, Karabouta Z, Pantoleon A, Rousso I. Investigation of anthropometric, biochemical and dietary parameters of obese children with and without non-alcoholic fatty liver disease. Appetite. 2012;59(3):939-944.
55. Jin R, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients. 2014;6(8):3187-3201.
56. Mager DR, Iniguez IR, Gilmour S, Yap J. The effect of a low fructose and low glycemic index/load (FRAGILE) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). JPEN J Parenter Enteral Nutr. 2015;39(1):73-84.
57. Lustig RH, et al. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome. Obesity (Silver Spring). 2016;24(2):453-460.
58. Ishimoto T, et al. High-fat and high-sucrose (western) diet induces steatohepatitis that is dependent on fructokinase. Hepatology. 2013;58(5):1632-1643.
59. Ishimoto T, et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci U S A. 2012;109(11):4320-4325.
60. Postic C, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knockouts using Cre recombinase. J Biol Chem. 1999;274(1):305-315.
61. Fitzgerald K, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2014;383(9911):60-68.
62. Fitzgerald K, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41-51.
63. Softic S, et al. Lipodystrophy due to adipose tissue-specific insulin receptor knockout results in progressive NAFLD. Diabetes. 2016;65(8):2187-2200.
64. Jensen MV, et al. Compensatory responses to pyruvate carboxylase suppression in islet beta-cells. Preservation of glucose-stimulated insulin secretion. J Biol Chem. 2006;281(31):22342-22351.
65. White PJ, et al. Branched-chain amino acid restriction in Zucker-fatty rats improves muscle insulin sensitivity by enhancing efficiency of fatty acid oxidation and acyl-glycine export. Mol Metab. 2016;5(7):538-551.